Psoriasis is a chronic skin condition that causes patches of red, dry, itchy skin, called plaques. When these plaques are not well treated, they can get itchy and flaky and then sometimes crack ...

The scales on psoriasis plaques are thicker than those of seborrheic dermatitis, with more defined edges. Their color is closer to silver than the white or yellow of seborrheic dermatitis scales ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

In the adolescent subgroup, 84.1% of patients treated with icotrokinra achieved IGA scores of 0/1 and 70.5% achieved PASI 90, compared with 27.3% and 13.6% receiving placebo, respectively, at week 16.

About Plaque PsoriasisPlaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.9 It ...

Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3 registrational study in moderate-to-severe plaque ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...